康乃德汰劣留良？实为弃车保帅
CN-Healthcare,
同样是II期结果不尽如意，康乃德对CBP-201（IL-4Rα抗体）的计划是“作为战略重点，今年下半年开始全球临床3期”，而对CBP-307（S1PR1小分子）的计划却是“为 CBP-307 寻求合作伙伴”。经过分析CBP-307的管线价值及战略调整的原因…
Intestinal Biomarkers Respond to Ozanimod
MedPage Today,
Meeting Coverage > CCC Fecal calprotectin and lactoferrin declined in ulcerative colitis by Contributing Writer, MedPage Today…
Ozanimod a Winner in Ulcerative Colitis
MedPage Today,
Meeting Coverage > AIBD S1P receptor modulator effective for both induction and maintenance by Contributing Writer, MedPage…
U.S. Biotech/Pharma Sector Daily Observations Letter: March 19, 2018
Seeking Alpha,
The overall market continued its sideways consolidation pattern with today being a down day (advancers: decliners= 21%: 71%).